Osteoporosis: DEXA Screening, Bisphosphonates, and FRAX Score

Osteoporosis is a systemic skeletal disease characterized by compromised bone strength predisposing to an increased risk of fracture. Bone strength reflects the integration of bone density and bone quality. [KEY_CONCEPT] The World Health Organization defines osteoporosis based on dual-energy X-ray absorptiometry (DEXA) measurements as a T-score ≤ -2.5 at the lumbar spine, femoral neck, or total hip.

Epidemiology:

• Affects >200 million people worldwide
• Postmenopausal women: 30% have osteoporosis, 54% have osteopenia
• Men >70 years: 5-6% prevalence
• Lifetime fracture risk: 50% in women, 20% in men over age 50

[HIGH_YIELD] Risk factors include:

• Non-modifiable: Age >65, female sex, Caucasian/Asian ethnicity, family history, small body frame
• Modifiable: Smoking, excessive alcohol, sedentary lifestyle, low calcium/vitamin D intake
• Medical conditions: Hyperparathyroidism, hyperthyroidism, chronic kidney disease, inflammatory conditions
• Medications: Glucocorticoids, anticonvulsants, PPIs (long-term use), aromatase inhibitors

Pathophysiology: Bone remodeling involves balanced osteoblast (bone formation) and osteoclast (bone resorption) activity. In osteoporosis, this balance shifts toward increased resorption, particularly after menopause due to estrogen deficiency. [CLINICAL_PEARL] Peak bone mass is achieved by age 30; thereafter, bone loss occurs at 0.5-1% annually, accelerating to 2-3% annually in the first decade after menopause.

[KEY_CONCEPT] Osteoporosis is often asymptomatic until fractures occur, earning it the nickname "silent disease." Most patients present after sustaining a fragility fracture - a fracture occurring from minimal trauma equivalent to a fall from standing height or less.

Common Fracture Sites:

• Vertebral compression fractures (most common)
• Hip fractures (most serious)
• Distal radius fractures (Colles' fractures)
• Proximal humerus fractures

Clinical Signs and Symptoms:

[CLINICAL_PEARL] Height loss >1.5 inches from peak adult height or prospective height loss >0.8 inches should prompt evaluation for vertebral fractures.

Physical Examination Findings:

• Wall-occiput distance: >7 cm suggests thoracic kyphosis
• Rib-pelvis distance: <2 finger breadths indicates vertebral compression
• Historical height measurement: Compare to driver's license or past medical records

[HIGH_YIELD] Patients may report chronic back pain that worsens with activity and improves with rest, particularly in the thoracic or lumbar regions. Many vertebral fractures (up to 2/3) are asymptomatic and discovered incidentally on imaging.

DEXA Scan Interpretation:

[KEY_CONCEPT] T-score compares patient's bone density to healthy 30-year-old of same sex and ethnicity at peak bone mass:

• Normal: T-score ≥ -1.0
• Osteopenia: T-score -1.0 to -2.5
• Osteoporosis: T-score ≤ -2.5
• Severe osteoporosis: T-score ≤ -2.5 + fragility fracture

Z-score compares to age-matched controls; Z-score ≤ -2.0 suggests secondary causes.

DEXA Screening Guidelines:

Screening Algorithm:

1. WOMEN:

   • Age ≥65: Screen all women
   • Age <65: Screen if risk factors present

2. MEN:

   • Age ≥70: Screen all men
   • Age 50-69: Screen if risk factors present

3. HIGH-RISK INDIVIDUALS:

   • Previous fragility fracture
   • Chronic glucocorticoid use
   • FRAX score indicates treatment threshold

FRAX Score Calculation: [HIGH_YIELD] The Fracture Risk Assessment Tool (FRAX) calculates 10-year probability of major osteoporotic fracture and hip fracture using:

• Age, sex, weight, height
• Previous fracture, family history
• Smoking, alcohol use
• Glucocorticoid use
• Secondary osteoporosis causes
• Femoral neck BMD (if available)

Treatment Thresholds (US Guidelines):

• 10-year hip fracture risk ≥3%
• 10-year major osteoporotic fracture risk ≥20%

Laboratory Workup:

• Complete blood count, comprehensive metabolic panel
• 25-hydroxyvitamin D, parathyroid hormone (PTH)
• Thyroid-stimulating hormone (TSH)
• 24-hour urine calcium (if hypercalciuria suspected)
• Consider: testosterone (men), celiac antibodies, serum/urine protein electrophoresis

[CLINICAL_PEARL] Vertebral fracture assessment (VFA) using DEXA can identify vertebral fractures in 15-20% of patients with osteopenia, potentially changing management recommendations.

Non-Pharmacological Management:

[KEY_CONCEPT] Lifestyle modifications form the foundation of osteoporosis management:

• Calcium: 1200 mg/day (women >50, men >70), 1000 mg/day (men 50-70)
• Vitamin D: 800-1000 IU/day, target 25(OH)D >30 ng/mL
• Weight-bearing exercise: 30 minutes, 3-4 times weekly
• Resistance training: 2-3 times weekly
• Fall prevention: Home safety assessment, balance training
• Smoking cessation and limit alcohol to <2 drinks/day

Pharmacological Management:

Bisphosphonate Selection and Dosing:

[HIGH_YIELD] First-line bisphosphonates:

• Alendronate: 70 mg weekly or 10 mg daily
• Risedronate: 35 mg weekly or 5 mg daily
• Ibandronate: 150 mg monthly or 3 mg IV every 3 months
• Zoledronic acid: 5 mg IV annually

Bisphosphonate Administration Guidelines:

Oral Bisphosphonate Protocol:

1. Take on empty stomach with 8 oz plain water
2. Remain upright for 30-60 minutes
3. No food, drink, or medications for 30-60 minutes
4. Contraindicated if unable to remain upright

[CLINICAL_PEARL] IV bisphosphonates are preferred for patients with:

• Gastrointestinal intolerance to oral formulations
• Malabsorption syndromes
• Inability to comply with administration requirements
• Esophageal disorders (stricture, achalasia)

Treatment Duration:

• Standard treatment: 3-5 years for most patients
• Drug holiday: Consider after 5 years if low fracture risk
• Extended therapy: Continue if high fracture risk (T-score ≤ -2.5, previous fracture)

Special Populations:

• Glucocorticoid-induced osteoporosis: Start bisphosphonates if ≥3 months of prednisone ≥5 mg/day
• Men: Same treatment thresholds and medications as postmenopausal women
• Premenopausal women: Generally avoid bisphosphonates due to long half-life

Bisphosphonate-Related Complications:

[HIGH_YIELD] Rare but serious adverse effects:

1. Osteonecrosis of the Jaw (ONJ):

• Incidence: 1 in 10,000-100,000 patients
• Risk factors: Dental procedures, poor oral hygiene, cancer, IV bisphosphonates
• Prevention: Dental evaluation before starting therapy
• Management: Discontinue bisphosphonates, conservative dental management

2. Atypical Femur Fractures:

• Incidence: 3.2-50 per 100,000 patient-years
• Presentation: Thigh pain, transverse/oblique fracture pattern
• Risk increases with duration >5 years
• Prodromal symptoms: Dull, aching thigh pain weeks to months before fracture

3. Esophageal Irritation:

• Most common with oral bisphosphonates
• Contraindications: Esophageal stricture, achalasia, inability to remain upright

Monitoring Protocol:

Monitoring Timeline:

Baseline:

• DEXA scan
• Complete metabolic panel, CBC
• 25(OH)D, PTH, TSH
• Dental evaluation

Ongoing Monitoring:

• DEXA scan every 2 years while on therapy
• Annual assessment of:
  • Calcium and vitamin D status
  • Fall risk and exercise habits
  • Medication adherence
  • New fractures or bone pain

Drug Holiday Consideration (after 3-5 years):

• If T-score improved to >-2.5
• No incident fractures
• Low fracture risk by FRAX

[CLINICAL_PEARL] Biochemical markers of bone turnover (CTX, P1NP) may be useful to monitor treatment response but are not routinely recommended in clinical practice.

Treatment Response Assessment:

• Adequate response: Stable or improved BMD, no new fractures
• Inadequate response: Continued bone loss >3-5%, new fragility fractures
• Consider secondary causes, medication adherence, or alternative therapies

Long-term Outcomes: [HIGH_YIELD] Fracture risk reduction with bisphosphonates:

• Vertebral fractures: 40-70% reduction
• Hip fractures: 40-50% reduction
• Non-vertebral fractures: 20-25% reduction

Patients should be counseled that fracture risk reduction is the primary goal, not necessarily BMD improvement, as fracture risk reduction often exceeds BMD changes.

Fracture Risk Stratification:

[KEY_CONCEPT] Hip fracture outcomes carry significant morbidity and mortality:

• 1-year mortality: 15-20% following hip fracture
• Functional decline: 50% never regain pre-fracture mobility
• Healthcare costs: >$18 billion annually in the US

Vertebral fracture cascade:

• Risk of subsequent vertebral fracture increases 5-fold after initial vertebral fracture
• Height loss and kyphosis can lead to restrictive lung disease and decreased quality of life

Treatment Efficacy Timeline:

Prevention Strategies:

Primary Prevention:

• Peak bone mass optimization in youth through adequate calcium, vitamin D, and exercise
• Lifestyle counseling starting in middle age
• Screening according to guidelines

Secondary Prevention:

• Post-fracture evaluation: All fragility fractures should prompt osteoporosis assessment
• Fracture liaison services: Systematic approach to identify and treat patients after fracture
• Fall prevention programs: Reduce fall risk in high-risk elderly

[CLINICAL_PEARL] Vertebral fracture assessment should be performed in all patients with height loss >1.5 inches, as up to 30% will have previously unrecognized vertebral fractures.

Special Considerations:

Glucocorticoid-Induced Osteoporosis (GIOP):

• Most rapid bone loss occurs in first 3-6 months
• Prevention: Start bisphosphonates with initiation of glucocorticoids if treatment duration expected >3 months
• Threshold: Lower treatment thresholds apply (FRAX adjustments available)

Male Osteoporosis:

• Often underdiagnosed and undertreated
• Same treatment efficacy as postmenopausal women
• Evaluate for secondary causes (hypogonadism, alcohol, medications)

Long-term Prognosis: With appropriate treatment:

• Fracture risk reduction maintained during therapy
• BMD preservation or modest improvement
• Quality of life improvement through reduced fracture risk and pain
• Cost-effective intervention in high-risk populations

[HIGH_YIELD] Drug holiday outcomes: After 3-5 years of bisphosphonate therapy, carefully selected patients may safely discontinue treatment for 2-3 years while maintaining fracture risk reduction, but require ongoing monitoring.